Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sNinj1-NP is a sustained-release nanoparticle formulation of a soluble ninjurin-1 (sNinj1)-mimetic peptide encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres. Developed by researchers at Asahikawa Medical University, sNinj1-NP mimics the cleaved extracellular domain of Ninjurin-1 (sNinj1) to exert anti-inflammatory and endothelial-protective effects. It competitively inhibits the homophilic adhesion and oligomerization of membrane-bound Ninjurin-1 (Ninj1), thereby suppressing macrophage activation, reducing the expression of pro-inflammatory cytokines (such as IL-6 and IL-1β), and preserving endothelial nitric oxide synthase (eNOS) expression. In preclinical models of cecum ligation puncture (CLP)-induced sepsis, sNinj1-NP administration significantly improved survival rates and attenuated sepsis-induced kidney dysfunction and acute kidney injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sNinj1-NP.